PET tau and amyloid-β burden in mild Alzheimer's disease: divergent relationship with age, cognition and cerebrospinal fluid biomarkers

PET tau and amyloid-β burden in mild Alzheimer's disease: divergent relationship with age, cognition and cerebrospinal fluid biomarkers

<strong>Background</strong> Combining PET amyloid-β and tau imaging may be critical for tracking disease progression in Alzheimer’s disease (AD). <strong>Objective</strong> We sought to characterize the relationship between amyloid-β and tau ligands as well as with other meas...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Koychev, I, Gunn, R, Firouzian, A, Lawson, J, Zamboni, G, Ridha, B, Sahakian, B, Rowe, J, Howard, R, Zetterberg, H, Mackay, C, Lovestone, S
Format:	Journal article
Veröffentlicht:	IOS Press 2017

Ähnliche Einträge

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
von: Firouzian, A, et al.
Veröffentlicht: (2018)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
von: Rosengren Lars, et al.
Veröffentlicht: (2009-12-01)

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
von: Azadeh Firouzian, et al.
Veröffentlicht: (2018-03-01)

Gait in mild Alzheimer’s disease: feasibility of multi-centre measurement in the clinic and home with body-worn sensors: a pilot study
von: Mc Ardle, R, et al.
Veröffentlicht: (2018)

Aβ42/Aβ40 and Aβ42/Aβ38 ratios are associated with measures of gait variability and activities of daily living in mild Alzheimer's disease: a pilot study
von: Koychev, I, et al.
Veröffentlicht: (2018)

Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning
von: Gihan P. Ruwanpathirana, et al.
Veröffentlicht: (2022-08-01)

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
von: Mandić Gorana, et al.
Veröffentlicht: (2008-01-01)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
von: Anna Rubinski, et al.
Veröffentlicht: (2020-10-01)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
von: Ross W. Paterson, et al.
Veröffentlicht: (2015-09-01)

Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type
von: Julien Lagarde, et al.
Veröffentlicht: (2021-09-01)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
von: Nicolas R. Barthélemy, et al.
Veröffentlicht: (2020-03-01)

Correlation of Alzheimer’s Disease neuropathologic staging with amyloid and tau scintigraphic imaging biomarkers
von: Koychev, I, et al.
Veröffentlicht: (2020)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
von: Seun Jeon, et al.
Veröffentlicht: (2019-08-01)

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
von: Westwood, S, et al.
Veröffentlicht: (2018)

Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics
von: Kocagoncu, E, et al.
Veröffentlicht: (2020)

Tau and amyloid-related pathologies in the entorhinal cortex have divergent effects in the hippocampal circuit
von: S.L. Angulo, et al.
Veröffentlicht: (2017-12-01)

Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review
von: Jhih-Yong Yang, et al.
Veröffentlicht: (2023-04-01)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
von: Samar Rahhal, et al.
Veröffentlicht: (2023-12-01)

Mobility and associations with levels of cerebrospinal fluid amyloid β and tau in a memory clinic cohort
von: Gro Gujord Tangen, et al.
Veröffentlicht: (2023-02-01)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
von: Umesh Gangishetti, et al.
Veröffentlicht: (2018-09-01)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
von: Taylor J. Maxwell, et al.
Veröffentlicht: (2018-08-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
von: Carla M. Startin, et al.
Veröffentlicht: (2019-03-01)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
von: Niklas Mattsson, et al.
Veröffentlicht: (2016-08-01)

Prediction of rapid amyloid and phospotylated-tau accumulation in cognitively healthy individuals
von: Koychev, I, et al.
Veröffentlicht: (2020)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
von: Niklas Mattsson‐Carlgren, et al.
Veröffentlicht: (2021-05-01)

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
von: Tapiola, T, et al.
Veröffentlicht: (2009)

Corrigendum to “Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency”
von: Samar Rahhal, et al.
Veröffentlicht: (2023-12-01)

Changes in Cerebrospinal Fluid Tau and β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis
von: Yanhui Lu, et al.
Veröffentlicht: (2018-10-01)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
von: Said HM, et al.
Veröffentlicht: (2022-04-01)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
von: Sarah Westwood, et al.
Veröffentlicht: (2018-12-01)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
von: Katherine W. Turk, et al.
Veröffentlicht: (2022-02-01)

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau
von: Vinay Banka, et al.
Veröffentlicht: (2023-05-01)

Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals
von: Ivan Koychev, et al.
Veröffentlicht: (2020-01-01)

Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau.
von: Aysha S Mohamed Lafirdeen, et al.
Veröffentlicht: (2019-01-01)

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
von: Koen Delmotte, et al.
Veröffentlicht: (2021-04-01)

Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse® platform
von: Marcella Catania, et al.
Veröffentlicht: (2025-01-01)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
von: Pieter Jelle Visser, et al.
Veröffentlicht: (2022-03-01)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
von: Ann De Vos, et al.
Veröffentlicht: (2017-08-01)

A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer’s Disease
von: Yunxing Ma, et al.
Veröffentlicht: (2022-07-01)

Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults
von: Breton M. Asken, et al.
Veröffentlicht: (2024-07-01)